Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The company recommends most patients begin with the 4-month "Jumpstart" program
Activating one does not inhibit the other
MiraviGLP released a retatrutide vendor ranking along with the full scoring system behind it, published as Miravi Score v1.0 in June 2026
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
The materials purchased by the clinic were labeled not for human use, but were nevertheless administered to paying patients
